Skip to main content

Main menu

  • Home
  • Content
    • Latest
    • Archive
    • home
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Institutions
    • Advertisers
    • Join SMJ
  • About Us
    • About Us
    • Editorial Office
    • Editorial Board
  • More
    • Advertising
    • Alerts
    • Feedback
    • Folders
    • Help
  • Other Publications
    • NeuroSciences Journal

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Saudi Medical Journal
  • Other Publications
    • NeuroSciences Journal
  • My alerts
  • Log in
Saudi Medical Journal

Advanced Search

  • Home
  • Content
    • Latest
    • Archive
    • home
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Institutions
    • Advertisers
    • Join SMJ
  • About Us
    • About Us
    • Editorial Office
    • Editorial Board
  • More
    • Advertising
    • Alerts
    • Feedback
    • Folders
    • Help
  • Follow psmmc on Twitter
  • Visit psmmc on Facebook
  • RSS
AbstractAbstract
Open Access

In this issueREVIEW ARTICLEORIGINAL ARTICLESCASE REPORT

Saudi Medical Journal October 2020, 41 (10) 1039;
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • References
  • PDF
Loading

REVIEW ARTICLE

Efficacy of gluten- and casein-free diets on autism spectrum disorders in children

Alamri investigste the role of gluten- and casein-free diet (GCFD) on the management of autism spectrum disorders (ASD). In total, 9 randomized controlled trials were included (521 participants) with age range between 2 to 18 years. Four of these studies did not show a significant improvement regarding the symptoms of ASD. The rest of these studies (n=5) showed improvement in communication, stereotyped movements, aggressiveness, language, hyperactivity, tantrums, and signs of attention deficit hyperactivity disorder compared to control group. Hence, the data remains insufficient to support the use of GCFD to improve the symptoms of ASD in children. A retrospective case-control study of all patients diagnosed with the great arteries (TGA) between 1999 to 2016 at King Abdulaziz Medical City, Riyadh, Saudi Arabia. Age and gender-matched controls were selected. To assess potential risk factors and their effect on the development of TGA.

see page 1041

ORIGINAL ARTICLES

Risk factors for transposition of the great arteries in Saudi population

Alfarhan et al assess potential risk factors and their effect on the development of transposition of the great arteries (TGA). All patients diagnosed with TGA between 1999 to 2016 at King Abdulaziz Medical City, Riyadh, Saudi Arabia. Age and gender-matched controls were selected. A total of 206 patients with transposition of the great arteries were enrolled in the study. In the studied cases, consanguinity was found in 95 of cases, gestational diabetes was diagnosed in 36 mothers, and 35 had a confirmed family history of congenital heart disease. The authors revealed significant risk factors for the development of transposition of great arteries including first degree consanguineous marriages, gestational diabetes, family history of congenital cardiac anomalies, and increasing maternal age and parity.

see page 1054

View this table:
  • View inline
  • View popup
  • Download powerpoint

Distribution of age at diagnosis and at surgery between transposition of the great arteries (TGA) typess

The current practice of using angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic hypertensive and non-hypertensive patients. Is there a room for vitamin D?

Sukkarieh et al conclude that ere is a universal agreement among physicians regarding the use of angiotensin-converting enzyme (ACE) and angiotensin II receptor blockers (ARBs) for the treatment of diabetic nephropathy (DN) with limited awareness of the benefits of using vitamin D. Hence, the development of specific guidelines for its use are recommended. The vast majority recommended clearer guidelines on monitoring renal function in patients treated with ACEi or ARBs. Forty-one physicians reported the use of combination therapy of ACEi and ARBs. Fifty-six physicians reported that they never used vitamin D in the treatment of DN, and 48% agreed that vitamin D can benefit patients with DN. The authors used the IBM SPSS 26.0 to perform descriptive statistical analyses and comparisons were based on the Chi-square test.

see page 1083

View this table:
  • View inline
  • View popup
  • Download powerpoint

Practices of the Use of ACE Inhibitors and ARBs (N=138)

CASE REPORT

Nasopharyngeal carcinoma metastasis to the breast

Albasri present a case of a 43-year-old Mauritanian female patient presented with a mass in her left breast and swelling in her left axillary region. A histopathological examination of the mass showed enlarged polygonal tumor cells with scant to moderate, eosinophilic to amphophilic cytoplasm and enlarged, hyperchromatic and pleomorphic nuclei with irregular nuclear membranes. An immunohistochemistry (IHC) examination was positive for pan cytokeratin and negative for CK7, CK20, S-100, LCA, HMB45, CD 20, desmin, myogenin, GCFDP-15, transcription factor-1, villin, estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. The patient was deceased 3 months after refusing the recommended medical intervention.

see page 1130

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Microphotography showing poorly differentiated malignant cells (hematoxylin-eosin at magni cation x 40)

  • Copyright: © Saudi Medical Journal

This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PreviousNext
Back to top

In this issue

Saudi Medical Journal: 41 (10)
Saudi Medical Journal
Vol. 41, Issue 10
1 Oct 2020
  • Table of Contents
  • Cover (PDF)
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Saudi Medical Journal.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
In this issueREVIEW ARTICLEORIGINAL ARTICLESCASE REPORT
(Your Name) has sent you a message from Saudi Medical Journal
(Your Name) thought you would like to see the Saudi Medical Journal web site.
Citation Tools
In this issueREVIEW ARTICLEORIGINAL ARTICLESCASE REPORT
Saudi Medical Journal Oct 2020, 41 (10) 1039;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
In this issueREVIEW ARTICLEORIGINAL ARTICLESCASE REPORT
Saudi Medical Journal Oct 2020, 41 (10) 1039;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • eLetters
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • In this issueSystematic ReviewOriginal ArticlesCase Report
  • In this issueSystematic ReviewOriginal Articles
  • In this issueClinical GuidelinesOriginal Articles
Show more Abstract

Similar Articles

CONTENT

  • home

JOURNAL

  • home

AUTHORS

  • home
Saudi Medical Journal

© 2025 Saudi Medical Journal Saudi Medical Journal is copyright under the Berne Convention and the International Copyright Convention.  Saudi Medical Journal is an Open Access journal and articles published are distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC). Readers may copy, distribute, and display the work for non-commercial purposes with the proper citation of the original work. Electronic ISSN 1658-3175. Print ISSN 0379-5284.

Powered by HighWire